Diabetes News

SAN DIEGO — Adults with type 2 diabetes naive to insulin therapy saw a long-term reduction in HbA1c and superior time in the recommended glucose range with once-weekly insulin icodec compared with daily insulin glargine, data show.

SAN DIEGO — In this video exclusive, David C. Klonoff, MD, FACP, FRCP (Edin), Fellow AIMBE, discusses the potential for data and AI to improve diabetes care.

SAN DIEGO — Combination cagrilintide and semaglutide therapy is associated with a 15.6% weight loss and 2.2% reduction in HbA1c among adults with obesity and type 2 diabetes, according to a speaker.

SAN DIEGO — In adults with elevated cardiovascular risk but without a prior clinical event and deemed statin intolerant, bempedoic acid reduced risk for major adverse CV events by 30% compared with placebo, researchers reported.

SAN DIEGO — Adults with obesity and type 2 diabetes achieved a 14.7% weight loss at 72 weeks with 15 mg tirzepatide, according to data from the SURMOUNT-2 trial presented at the American Diabetes Association Scientific Sessions.

SAN DIEGO — Diabetes and nonalcoholic fatty liver disease are “common bedfellows” due to processes brought on by insulin resistance, but a reduction in dietary sugars combined with exercise can reverse the damage, according to a speaker.

SAN DIEGO — In this video exclusive, Osagie Ebekozien, MD, MPH, CPHQ, chief medical officer at T1D Exchange, describes research being undertaken by the organization.

SAN DIEGO — Adults with obesity and without diabetes receiving the oral GLP-1 receptor agonist orforglipron lost 8.6% to 12.6% of their body weight at 26 weeks, according to a data from a phase 2 trial.

SAN DIEGO — Silva A. Arslanian, MD, wishes she could pick the brain of “visionary” Apple founder Steve Jobs — “How did he come up with these ideas? Did he dream them at night?” — and respects billionaire MacKenzie Scott’s mammoth charitable donations.

SAN DIEGO — Children with type 1 diabetes who began using a continuous glucose monitor within 6 months of diagnosis had a lower HbA1c at 3 years than those who started CGM 6 to 12 months after diagnosis, according to a speaker.